• 제목/요약/키워드: Malignant pleural mesothelioma (MPM)

검색결과 16건 처리시간 0.027초

Caring for Patients with Malignant Pleural Mesothelioma in Japan: Evaluation of a Palliative Care Educational Program

  • Nagamatsu, Yasuko;Nakayama, Yukiko;Clayson, Helen;Natori, Yuji;Ohata, Misato;Matsuura-Moriguchi, Shino;Porter, Sarah E.
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권21호
    • /
    • pp.9165-9170
    • /
    • 2014
  • Purpose: This study evaluated the effect of an Educational Program on Palliative Care for MPM for Nurses in Japan. Program: The 5-h program consisted of lectures and care planning group work. Materials and Methods: This study used a pretest-posttest design with a single cohort of nurses and included a Difficulties in Palliative Care for Patients with MPM (DPCMPM) Scale with 15 items. The pre- and posttest scores were compared using a t-test. Results: We included 27 female nurses with a mean of 14.4 years of nursing experience. In 12 of 15 DPCMPM items, the posttest difficulty scores were lower than the pretest scores. Participants highly evaluated the program for validity, clarity, clinical usefulness, and the facilitators. The Palliative Care for MPM Handbook for Nurses was developed as an educational tool for clinical settings. Conclusions: The Educational Program on Palliative Care for MPM for Nurses was effective in reducing nursing difficulties.

Secondline Chemotherapy Versus Best Supportive Care in Patient with Malignant Pleural Mesothelioma: A Retrospective Study

  • Mutlu, Hasan;Buyukcelik, Abdullah;Karaca, Halit;Aksahin, Arzu;Berk, Veli;Aslan, Tuncay;Erden, Abdulsamet;Akca, Zeki;Ozkan, Metin
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권6호
    • /
    • pp.3887-3889
    • /
    • 2013
  • Introduction: Mesothelioma is a rare neoplasm arising from mesothelial surfaces with the malignant pleural mesothelioma (MPM) as the most common form. Secondline chemotherapy in MPM is still controversial and in this study we evaluated whether it is superior to best supportive care. Materials and Methods: A total of 51 patients with MPM from Acibadem Kayseri Hospital, Kayseri Training and Research Hospital and Erciyes University were analyzed retrospectively. The patients treated with secondline chemotherapies (SLCT) were compared with those treated with best supportive care (BSC) for overall survival. Results: The median overall survival (OS) for firstline chemotherapy${\rightarrow}$SLCT and firstline chemotherapy${\rightarrow}$BSC groups were 20.3 and 14.7 months respectively (p=0.079). After firstline chemotherapy the median OS for SLCT and BSC were 5.9 and 4.7 months (p=0.355). Discussion: Although there was a trend for improvement in overall survival in patients treated with secondline chemotherapy, the difference was not statistically significant. Our results do not support the proposal that secondline chemotherapy could be effective in patients with MPM.

Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery

  • Na, Bub-Se;Kim, Ji Seong;Hyun, Kwanyong;Park, In Kyu;Kang, Chang Hyun;Kim, Young Tae
    • Journal of Chest Surgery
    • /
    • 제51권1호
    • /
    • pp.35-40
    • /
    • 2018
  • Background: The treatment of malignant pleural mesothelioma (MPM) is challenging, and multimodal treatment including surgery is recommended; however, the role of surgery is debated. The treatment outcomes of MPM in Korea have not been reported. We analyzed the outcomes of MPM in the context of multimodal treatment, including surgery. Methods: The records of 29 patients with pathologically proven MPM from April 1998 to July 2015 were retrospectively reviewed. The treatment outcomes of the surgery and non-surgery groups were compared. Results: The overall median survival time was 10.6 months, and the overall 3-year survival rate was 25%. No postoperative 30-day or in-hospital mortality occurred in the surgery group. Postoperative complications included tachyarrhythmia (n=4), pulmonary thromboembolism (n=1), pneumonia (n=1), chylothorax (n=1), and wound complications (n=3). The treatment outcomes between the surgery and non-surgery groups were not significantly different (3-year survival rate: 31.3% vs. 16.7%, respectively; p=0.47). In a subgroup analysis, there was no significant difference in the treatment outcomes between the extrapleural pneumonectomy group and the non-surgery group (3-year survival rate: 45.5% vs. 16.7%, respectively; p=0.23). Conclusion: Multimodal treatment incorporating surgery did not show better outcomes than non-surgical treatment. A nationwide multicenter data registry and prospective randomized controlled studies are necessary to optimize the treatment of MPM.

Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma

  • Hong, Ji Hyun;Lee, Hyo Chun;Choi, Kyu Hye;Moon, Seok Whan;Kim, Kyung Soo;Hong, Suk Hee;Hong, Ju-Young;Kim, Yeon-Sil;Multidisciplinary Team of Lung Cancer in Seoul St. Mary's Hospital
    • Radiation Oncology Journal
    • /
    • 제37권2호
    • /
    • pp.101-109
    • /
    • 2019
  • Purpose: The purpose of this study is to evaluate the safety and efficacy of the multimodality treatment with neoadjuvant intensity-modulated radiotherapy (IMRT) for resectable clinical T1-3N0-1M0 malignant pleural mesothelioma (MPM). Materials and Methods: A total of eleven patients who received neoadjuvant chemotherapy and radiotherapy between March 2016 and June 2018 were reviewed. Patients received 25 Gy in 5 fractions to entire ipsilateral hemithorax with helical tomotherapy. Results: All of patients were men with a median age of 56 years. Epithelioid subtype was found in 10 patients. All patients received neoadjuvant chemotherapy with pemetrexed-cisplatin regimen. Ten patients (90.9%) completed 25 Gy/5 fractions and one (9.0%) completed 20 Gy/4 fractions of radiotherapy. IMRT was well tolerated with only one acute grade 3 radiation pneumonitis. Surgery was performed 1 week (median, 8 days; range, 1 to 15 days) after completing IMRT. Extrapleural pneumonectomy was performed in 4 patients (36.3%), extended pleurectomy/decortication in 2 (18.2%) and pleurectomy/decortications in 5 (63.6%). There was no grade 3+ surgical complication except two deaths after EPP in 1 month. Based on operative findings and pathologic staging, adjuvant chemotherapy was delivered in 7 patients (63.6%), and 2 (18.2%) were decided to add adjuvant radiotherapy. After a median follow-up of 14.6 months (range, 2.8 to 30 months), there were 3 local recurrence (33.3%) and 1 distant metastasis (11.1%). Conclusion: Neoadjuvant entire pleural IMRT can be delivered with a favorable radiation complication. An optimal strategy has to be made in resectable MPM patients who would benefit from neoadjuvant radiation and surgery. Further studies are needed to look at long-term outcomes.

악성흉막중피종의 병기판정에서 자기공명영상의 진단적 유용성 평가 (Added Value of Magnetic Resonance Imaging in Staging of Malignant Pleural Mesothelioma)

  • 이은솔;채은진;강선지;염유경;이현주;박종천;신소연;최윤영;최준호;도경현
    • Investigative Magnetic Resonance Imaging
    • /
    • 제17권3호
    • /
    • pp.232-238
    • /
    • 2013
  • 목적 : 악성흉막중피종 (이하 MPM)의 임상적 병기판정에 있어 자기공명영상 (이하 MR)의 진단적 유용성을 컴퓨터단층촬영(이하 CT)과 비교하였다. 대상 및 방법 : 1997년부터 2012년까지 MPM으로 확인된 환자 중 진단 시 CT와 MR을 얻은 환자 20명 (남:여=14:6; 평균연령= 53.5세)을 대상으로 하였다. CT 혹은 MR 단독을 이용하여 두 명의 영상의학과 의사가 의견 일치 하에 병기판정을 시행하였다. 수술적 병기판정을 받은 환자의 경우 이와 비교하여 CT 단독 및 CT와 MR을 함께 시행하였을 때의 진단적 정확도를 평가하였다. 또 CT 단독과 CT와 MR을 함께 시행하였을 때의 임상병기의 일치도를 비교하였다. 결과 : CT를 이용한 T stage의 정확도는 23.1% (3/13)였고 MR과 함께 시행한 경우 38.5% (5/13)였다. CT 및 MR을 함께 시행한 경우 수술 후 수술적 병기에서 5명의 환자는 상위 진단을, 3명의 환자는 하위 진단을 보였다. CT 단독 및 CT와 MR을 함께 시행한 병기를 서로 비교하였을 때 85.0% (17/20)의 일치도를 보였고 불일치한 예(3명)에서는 함께 시행한 경우 CT 단독보다 상위 진단을 하였다. 결론 : MPM의 병기판정에 있어서 MR을 함께 시행한 경우 CT 단독에 비해 보다 높은 정확도의 병기판정을 제공하여 수술대상이 되는 환자에서 수술 전 검사로서 중요한 역할을 수행할 것으로 기대된다.

Surgical Options for Malignant Mesothelioma: A Single-Center Experience

  • Kang, Seung Ri;Bok, Jin San;Lee, Geun Dong;Choi, Se Hoon;Kim, Hyeong Ryul;Kim, Dong Kwan;Park, Seung-Il;Kim, Yong-Hee
    • Journal of Chest Surgery
    • /
    • 제51권3호
    • /
    • pp.195-201
    • /
    • 2018
  • Background: We investigated the surgical outcomes of patients who underwent therapeutic surgery for malignant pleural mesothelioma (MPM) at a single center. Methods: A retrospective review of 21 patients who underwent therapeutic surgery for MPM from January 2001 to June 2015 was conducted to assess their outcomes. The patients' characteristics and postoperative course, including complications, mortality, overall survival, and recurrence-free survival, were analyzed. Results: Of the 21 patients who underwent therapeutic surgery, 1 5 (71.4%) underwent extrapleural pneumonectomy, 2 pleurectomy (9.5%), and 4 excision (1 9.1 %). The median age was 57 years (range, 32-79 years) and 15 were men (71.4%). The mean hospital stay was 1 6 days (range, 1-63 days). Median survival was 14.3 months. The survival rate was 54.2%, 35.6%, and 21.3% at 1, 3, and 5 years, respectively. In patients' postoperative course, heart failure was a major complication, occurring in 3 patients (14.3%). The in-hospital mortality rate was 2 of 21 (9.5%) due to a case of severe pneumonia and a case of acute heart failure. Conclusion: A fair 5-year survival rate of 21.3% was observed after surgical treatment. Heart failure was a major complication in our cohort. Various surgical methods can be utilized with MPM, each with its own benefits, taking into consideration the severity of the disease and the comorbidities of the patient. Patients with local recurrence may be candidates for surgical intervention, with possible satisfying results.